Your browser is no longer supported. Please, upgrade your browser.
OPKO Health, Inc.
Index- P/E24.66 EPS (ttm)0.12 Insider Own4.50% Shs Outstand651.84M Perf Week-34.31%
Market Cap2.04B Forward P/E45.47 EPS next Y0.06 Insider Trans1.78% Shs Float410.71M Perf Month-43.50%
Income75.90M PEG2.06 EPS next Q-0.02 Inst Own28.40% Short Float12.20% Perf Quarter-19.17%
Sales1.87B P/S1.09 EPS this Y109.00% Inst Trans0.47% Short Ratio9.26 Perf Half Y-25.19%
Book/sh2.71 P/B1.07 EPS next Y45.45% ROA3.10% Target Price6.90 Perf Year-47.66%
Cash/sh0.21 P/C13.72 EPS next 5Y12.00% ROE4.40% 52W Range3.00 - 6.27 Perf YTD-39.50%
Dividend- P/FCF44.32 EPS past 5Y22.70% ROI2.10% 52W High-53.59% Beta1.72
Dividend %- Quick Ratio1.60 Sales past 5Y23.90% Gross Margin34.70% 52W Low-3.00% ATR0.33
Employees5269 Current Ratio2.00 Sales Q/Q-9.90% Oper. Margin7.00% RSI (14)26.48 Volatility8.15% 6.35%
OptionableYes Debt/Eq0.12 EPS Q/Q19.10% Profit Margin4.10% Rel Volume2.05 Prev Close3.01
ShortableYes LT Debt/Eq0.11 EarningsOct 28 AMC Payout0.00% Avg Volume5.41M Price2.91
Recom1.40 SMA20-34.69% SMA50-32.09% SMA200-25.75% Volume11,472,982 Change-3.32%
Jan-24-22Downgrade Barrington Research Outperform → Mkt Perform
Jun-21-21Initiated Ladenburg Thalmann Buy $7
Nov-25-19Initiated Piper Jaffray Overweight $2.50
Mar-02-18Downgrade JP Morgan Neutral → Underweight
Sep-14-17Downgrade JP Morgan Overweight → Neutral
Jun-21-16Reiterated Standpoint Research Buy $16 → $18
Jun-03-16Initiated Standpoint Research Buy $16
Mar-31-16Reiterated Barrington Research Outperform $17 → $16
Oct-16-15Initiated JP Morgan Overweight $14
Sep-11-15Downgrade Jefferies Buy → Hold
Mar-03-15Downgrade Oppenheimer Outperform → Perform
May-12-14Reiterated Oppenheimer Outperform $13 → $12
Mar-14-14Initiated Oppenheimer Outperform $13
Nov-13-13Reiterated Ladenburg Thalmann Buy $10 → $14.50
May-30-13Reiterated Ladenburg Thalmann Buy $8.50 → $10
Oct-22-12Initiated Barrington Research Outperform $6
Dec-01-11Reiterated Ladenburg Thalmann Buy $6 → $8.50
Jul-14-11Initiated Ladenburg Thalmann Buy $6
Jan-24-22 04:44PM  
Jan-21-22 04:30PM  
Jan-20-22 08:00AM  
Jan-18-22 09:38AM  
Jan-05-22 04:05PM  
Dec-27-21 11:07AM  
Dec-23-21 01:56PM  
Dec-09-21 12:00PM  
Dec-08-21 08:00AM  
Dec-06-21 08:00AM  
Dec-03-21 07:16AM  
Nov-30-21 10:13AM  
Nov-29-21 10:25AM  
Nov-01-21 09:12AM  
Oct-29-21 02:05PM  
Oct-28-21 06:15PM  
Oct-25-21 10:57AM  
Oct-12-21 08:00AM  
Oct-05-21 06:50AM  
Oct-04-21 01:01PM  
Sep-27-21 09:45AM  
Sep-24-21 04:24PM  
Sep-21-21 02:30PM  
Sep-15-21 10:50AM  
Sep-14-21 08:00AM  
Aug-30-21 04:17PM  
Aug-26-21 09:18AM  
Aug-17-21 10:47AM  
Aug-16-21 09:55AM  
Aug-05-21 09:53AM  
Jul-30-21 05:24PM  
Jul-29-21 07:15PM  
Jul-22-21 03:03PM  
Jul-20-21 08:00AM  
Jul-16-21 07:01AM  
Jul-13-21 12:03PM  
Jul-12-21 10:59AM  
Jul-08-21 04:05PM  
Jun-28-21 09:32AM  
Jun-22-21 08:30AM  
Jun-21-21 11:01AM  
Jun-19-21 05:07AM  
Jun-17-21 08:25AM  
May-28-21 11:31AM  
May-27-21 08:30AM  
May-25-21 04:49AM  
May-24-21 07:30AM  
May-23-21 08:08AM  
May-20-21 08:55AM  
May-07-21 01:34PM  
Apr-29-21 09:06AM  
Apr-28-21 10:31PM  
Apr-27-21 08:38AM  
Apr-22-21 08:00AM  
Apr-06-21 08:44AM  
Apr-01-21 08:28AM  
Mar-30-21 12:00PM  
Mar-26-21 08:25AM  
Mar-20-21 11:30AM  
Mar-08-21 11:21AM  
Feb-22-21 11:51AM  
Feb-19-21 06:14AM  
Feb-18-21 04:38PM  
Feb-17-21 10:11AM  
Feb-03-21 09:01AM  
Jan-28-21 08:00AM  
Jan-26-21 08:30AM  
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FROST PHILLIP MD ET ALCEO & ChairmanJan 26Buy2.98350,0001,041,817193,521,694Jan 27 08:12 AM
FROST PHILLIP MD ET ALCEO & ChairmanSep 14Buy3.46100,000346,443193,171,694Sep 15 07:09 AM
FROST PHILLIP MD ET ALCEO & ChairmanAug 13Buy3.69100,000368,987193,071,694Aug 16 08:33 AM
HSIAO JANE PH DVice Chairman & CTOAug 09Buy3.73103727,599,870Aug 10 04:12 PM
FROST PHILLIP MD ET ALCEO & ChairmanJun 14Buy3.62200,000723,927192,971,694Jun 15 07:24 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 25Buy3.64400,0001,455,972192,771,694May 26 07:42 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 10Buy3.6575,000273,745192,371,694May 11 07:36 AM
Cohen Jon RSVP OPKO; Exec Chairman BRLIMay 10Buy3.8150,000190,500125,000Jun 01 02:41 PM
FROST PHILLIP MD ET ALCEO & ChairmanMay 07Buy3.8475,000287,742192,296,694May 10 07:25 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 06Buy3.9125,00097,782192,221,694May 07 07:04 AM
FROST PHILLIP MD ET ALCEO & ChairmanMay 04Buy3.9425,00098,481192,196,694May 05 07:59 AM
FROST PHILLIP MD ET ALCEO & ChairmanMar 05Buy3.91300,0001,173,841192,171,694Mar 08 07:20 AM
FROST PHILLIP MD ET ALCEO & ChairmanFeb 19Buy4.77500,0002,383,455191,871,694Feb 22 07:37 AM